A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial

Gnanandarajah, Josephine S; Ndikuyeze, Georges Habineza; Engiles, Julie B; Wallecha, Anu; Mason, Nicola

doi:10.1186/2051-1426-2-S3-P55

Article metrics
Last updated: Thu, 25 Apr 2024 8:24:30 Z

A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial

Access & Citations

813

Article Accesses
0

Web of Science
1

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.